Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2008

Open Access 01-12-2008 | Research article

Human Papillomavirus type distribution in invasive cervical cancer in Uganda

Authors: Michael Odida, Silvia de Sanjosé, Wim Quint, Xavier F Bosch, Joellen Klaustermeier, Elisabete Weiderpass

Published in: BMC Infectious Diseases | Issue 1/2008

Login to get access

Abstract

Background

We conducted a study aiming to describe Human Papillomavirus (HPV) type distribution in invasive cervical carcinoma in Uganda.

Methods

191 archival cervical carcinoma samples diagnosed in the Department of Pathology, Makerere University in Kampala between 1968 and 1992 were analysed using a sensitive PCR-Reverse Hybridization Line Probe Assay.

Results

Out of the 186 cases of confirmed invasive cervical cancer in the study paraffin blocks, 114 were positive for HPV DNA. Specific HPV genotypes were identifiable in 109 cases: HPV 16, 18, 31, 35, 39, 44, 45, 51, 52 and 70. These occurred as single infections in 105 cases (96.3%) and as multiple infections in 4 cases (3.7%). HPV 16 or 18 accounted for 80% (84/105) of cases with single infection.

Conclusion

The results of this study confirm the role of HPV 16 and 18 in cervical cancer pathogenesis in the Ugandan population. The results suggest that the currently available HPV vaccines against HPV 16 and 18 could possibly prevent the majority of invasive cervical cancers in Uganda.
Literature
1.
Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006, 98: 303-315.CrossRefPubMed
2.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.CrossRefPubMed
3.
zur Hausen H: Papillomavirus infections – a major cause of human cancers. Biochim Biophys Acta. 1996, 1288: F55-F78.PubMed
4.
Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995, 87: 796-802. 10.1093/jnci/87.11.796.CrossRefPubMed
5.
Munoz N, Bosch FX, de Sanjose S, Tafur L, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N: The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer. 1992, 52: 743-749. 10.1002/ijc.2910520513.CrossRefPubMed
6.
Chichareon S, Herrero R, Munoz N, Bosch FX, Jacobs MV, Deacon J, Santamaria M, Chongsuvivatwong V, Meijer CJ, Walboomers JM: Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst. 1998, 90: 50-57. 10.1093/jnci/90.1.50.CrossRefPubMed
7.
Tase T, Sato S, Wada Y, Yajima A, Okagaki T: Prevalence of human papillomavirus type 18 DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix occurring in Japan. Tohoku J Exp Med. 1988, 156: 47-53. 10.1620/tjem.156.47.CrossRefPubMed
8.
Wilczynski SP, Bergen S, Walker J, Liao SY, Pearlman LF: Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types. Hum Pathol. 1988, 19: 697-704. 10.1016/S0046-8177(88)80176-X.CrossRefPubMed
9.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007, 121: 621-632. 10.1002/ijc.22527.CrossRefPubMed
10.
Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003, 88: 63-73. 10.1038/sj.bjc.6600688.CrossRefPubMedPubMedCentral
11.
Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006, 367: 1247-1255. 10.1016/S0140-6736(06)68439-0.CrossRefPubMed
12.
Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006, 107: 18-27.CrossRefPubMed
13.
Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006, 95: 1459-1466. 10.1038/sj.bjc.6603469.CrossRefPubMedPubMedCentral
14.
Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, ter Harmsel B, Quint W: Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998, 153: 1731-1739.CrossRefPubMedPubMedCentral
15.
Rughooputh S, Eddoo R, Manraj S, Jeebun N, Greenwell P: Detection of human papillomavirus from archival tissues in cervical cancer patients in Mauritius. J Clin Virol. 2006, 35: 173-178. 10.1016/j.jcv.2005.03.010.CrossRefPubMed
16.
Bertelsen BI, Kugarajh K, Skar R, Laerum OD: HPV subtypes in cervical cancer biopsies between 1930 and 2004: detection using general primer pair PCR and sequencing. Virchows Arch. 2006, 449: 141-147. 10.1007/s00428-006-0232-3.CrossRefPubMed
17.
Quint W, Brunsveld JP, Klaustermeier J, de Sanjose S, Lloveras B, Font R, Sanchez GI, Tous S, Molijn A, Munoz N, Bosch FX: Search of the appropriate algorithm for the evaluation of HPV negative blocks of invasive cervical cancer [abstract]. Book of Abstracts. 23rd International Papillomavirus Conference and Clinical Workshop. 2006, 363-
18.
Hammouda D, Munoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, Djedeat B, Fontaniere B, Snijders P, Meijer C, Franceschi S: Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors. Int J Cancer. 2005, 113: 483-489. 10.1002/ijc.20600.CrossRefPubMed
19.
Castellsague X, Klaustermeier J, Carrilho C, Albero G, Sacarlal J, Quint W, Kleter B, Lloveras B, Ismail MR, de Sanjosé S, Bosch FX, Alonso P, Menéndez C: Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: Burden and potential for prevention. Int J Cancer. 2008, 122: 1901-1904. 10.1002/ijc.23292.CrossRefPubMed
20.
Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Viladiu P, Navarro C, Martos C, Ascunce N: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004, 111: 278-285. 10.1002/ijc.20244.CrossRefPubMed
21.
An HJ, Kim KR, Kim IS, Kim DW, Park MH, Park IA, Suh KS, Seo EJ, Sung SH, Sohn JH, Yoon HK, Chang ED, Cho HI, Han JY, Hong SR, Ahn GH: Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol. 2005, 18: 528-534. 10.1038/modpathol.3800316.CrossRefPubMed
22.
de Sanjose S, Quint W, Klaustermeier J, Lloveras B, Brunsveld JP, Font R, Guimera N, Garland S, Nessa A, Qiao YL, Grce M, Clavel C, Lombardi L, Ferrera A, Bhatla N, Jain A, Mariani L, Sasawaga T, Menendez C, Banjo K, Domingo EJ, Ordi J, Chou CY, Chichareon S, Usubutun A, Oliva E, Wright TC, Garcia V, Sanchez GI, Munoz N, Bosch FX: HPV Type Distribution In Invasive Cervical Cancer: The Worldwide Perspective [abstract]. Abstract Book. 24th International Papillomavirus Conference and Clinical Workshop. 2007, 32-
23.
Carrilho C, Gouveia P, Cantel M, Alberto M, Buane L, David L: Characterization of human papillomavirus infection, P53 and Ki-67 expression in cervix cancer of Mozambican women. Pathol Res Pract. 2003, 199: 303-311. 10.1078/0344-0338-00422.CrossRefPubMed
24.
Eluf-Neto J, Booth M, Munoz N, Bosch FX, Meijer CJ, Walboomers JM: Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer. 1994, 69: 114-119.CrossRefPubMedPubMedCentral
25.
Chaouki N, Bosch FX, Munoz N, Meijer CJ, El Gueddari B, El Ghazi A, Deacon J, Castellsague X, Walboomers JM: The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer. 1998, 75: 546-554. 10.1002/(SICI)1097-0215(19980209)75:4<546::AID-IJC9>3.0.CO;2-T.CrossRefPubMed
26.
Santos C, Munoz N, Klug S, Almonte M, Guerrero I, Alvarez M, Velarde C, Galdos O, Castillo M, Walboomers J, Meijer C, Caceres E: HPV types and cofactors causing cervical cancer in Peru. Br J Cancer. 2001, 85: 966-971. 10.1038/sj.bjc.6691948.CrossRefPubMedPubMedCentral
27.
Rolon PA, Smith JS, Munoz N, Klug SJ, Herrero R, Bosch X, Llamosas F, Meijer CJ, Walboomers JM: Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer. 2000, 85: 486-491. 10.1002/(SICI)1097-0215(20000215)85:4<486::AID-IJC7>3.0.CO;2-S.CrossRefPubMed
28.
Huang HJ, Huang SL, Lin CY, Lin RW, Chao FY, Chen MY, Chang TC, Hsueh S, Hsu KH, Lai CH: Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int J Gynecol Cancer. 2004, 14: 639-649. 10.1111/j.1048-891X.2004.14418.x.CrossRefPubMed
29.
Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M: Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000, 92: 464-474. 10.1093/jnci/92.6.464.CrossRefPubMed
30.
Naucler P, Da Costa FM, Ljungberg O, Bugalho A, Dillner J: Human papillomavirus genotypes in cervical cancers in Mozambique. J Gen Virol. 2004, 85: 2189-2190. 10.1099/vir.0.80001-0.CrossRefPubMed
31.
Huang LW, Chao SL, Chen PH, Chou HP: Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues. J Clin Virol. 2004, 29: 271-276. 10.1016/S1386-6532(03)00167-7.CrossRefPubMed
32.
Lee SA, Kang D, Seo SS, Jeong JK, Yoo KY, Jeon YT, Kim JW, Park NH, Kang SB, Lee HP, Song YS: Multiple HPV infection in cervical cancer screened by HPVDNAChip. Cancer Lett. 2003, 198: 187-192. 10.1016/S0304-3835(03)00312-4.CrossRefPubMed
33.
Moodley JR, Hoffman M, Carrara H, Allan BR, Cooper DD, Rosenberg L, Denny LE, Shapiro S, Williamson AL: HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer. 2006, 6: 135-10.1186/1471-2407-6-135.CrossRefPubMedPubMedCentral
34.
Gichangi PB, Bwayo J, Estambale B, De Vuyst H, Ojwang S, Rogo K, Abwao H, Temmerman M: Impact of HIV infection on invasive cervical cancer in Kenyan women. AIDS. 2003, 17: 1963-1968. 10.1097/00002030-200309050-00015.CrossRefPubMed
35.
ter Meulen J, Eberhardt HC, Luande J, Mgaya HN, Chang-Claude J, Mtiro H, Mhina M, Kashaija P, Ockert S, Yu X: Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, east Africa. Int J Cancer. 1992, 51: 515-521. 10.1002/ijc.2910510403.CrossRefPubMed
36.
UNAIDS/WHO: Epidemiological Fact Sheet on HIV/AIDS and Sexually Transmitted Infections, Uganda. Geneva. 1998
Metadata
Title
Human Papillomavirus type distribution in invasive cervical cancer in Uganda
Authors
Michael Odida
Silvia de Sanjosé
Wim Quint
Xavier F Bosch
Joellen Klaustermeier
Elisabete Weiderpass
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2008
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-8-85

Other articles of this Issue 1/2008

BMC Infectious Diseases 1/2008 Go to the issue

Research article

Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis

Research article

Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study

Research article

Sustained high prevalence of sexually transmitted infections among female sex workers in Cambodia: high turnover seriously challenges the 100% condom use programme

Research article

Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission

Research article

Neonatal tetanus in Turkey; what has changed in the last decade?

Research article

The United States and Canada as a coupled epidemiological system: An example from hepatitis A
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits